On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.

Pfizer’s blockbuster vaccine Prevenar 13 will soon get a boost in a host of international markets. The shot won WHO backing in a new, easier-to-store…

On the heels of a $42 million supply contract with the U.S. Department of Defense, France’s Valneva has netted another big funding source. Through a loan with…

Just as efforts to develop a vaccine against Zika intensified this month, Congress left on vacation without passing a Zika funding bill, potentially delaying…

Already the world’s best-selling vaccine, Pfizer’s Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49.

Even as some of the world’s largest drugmakers ante up in the Zika vaccine hunt, some smaller biotechs are looking to play their part in the search for a…

After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National…

Lending its vaccines expertise to a leading Zika candidate, Sanofi has teamed up with the U.S. Army’s Walter Reed Army Institute of Research to guide an…

Researchers already knew that the protection offered by GlaxoSmithKline’s malaria vaccine--the world’s first--wanes over time. But new data shows it may…